ReviewCancer science2008
Cancer cells survive with survivin.
Review in Cancer science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.
- Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies.Journal of cancer research and clinical oncology · 2014Pooled it
- Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer.Immuno-oncology technology · 2026Review
- Overcoming Resistance: Targeting Survivin-Driven Apoptotic Resistance Restores Irinotecan Sensitivity inCancers · 2026Article
- Establishment of the Prognostic Signature with Genes Related to G2/M Checkpoint in Hepatocellular Carcinoma.Biochemical genetics · 2025Article
- Molecular Targets for Breast Cancer Therapy.Biomolecules · 2024Article
- Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms.Biological trace element research · 2023Article
- Designing Nanomedicines for Breast Cancer Therapy.Biomolecules · 2023Article
- The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer.Cancers · 2022Article
- Tumor-targeted fluorescence labeling systems for cancer diagnosis and treatment.Cancer science · 2022Review
- Identification of potential prognostic biomarkers for hepatocellular carcinoma.Journal of gastrointestinal oncology · 2022Article
- Establishment and validation of a novel immune-related prognostic signature in malignant pleural mesothelioma.Annals of translational medicine · 2022Article
- BIRC5 promotes cancer progression and predicts prognosis in laryngeal squamous cell carcinoma.PeerJ · 2022Article
- The N6-Methylandenosine-Related GeneFrontiers in molecular biosciences · 2022Article
- Lactoferrin: A Nutraceutical with Activity against Colorectal Cancer.Frontiers in pharmacology · 2022Review
- Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).RSC medicinal chemistry · 2021Article
- miR-101-3p sensitizes lung adenocarcinoma cells to irradiation via targeting BIRC5.Oncology letters · 2021Article
- Depletion of Survivin suppresses docetaxel-induced apoptosis in HeLa cells by facilitating mitotic slippage.Scientific reports · 2021Article
- Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence.Frontiers in genetics · 2021Article
- Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells.International journal of molecular sciences · 2020Review
- YM155, specific survivin inhibitor, can enhance artesunate-induced cytotoxicity in HCT116 colon cancer cells.Korean journal of clinical oncology · 2020Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favor cancer survival. Many studies on clinical specimens have shown that survivin expression is invariably up-regulated in human cancers and is associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. It is also reported that survivin inhibition, alone or in combination with the other therapies, induces or enhances apoptosis and mitotic catastrophe in tumor cells. Moreover, certain antitumor agents can reduce survivin expression. These findings suggest that survivin may be a promising molecular target against human malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.